Try our Advanced Search for more refined results
NOVO NORDISK INC. et al v. BECERRA et al
Case Number:
3:23-cv-20814
Court:
Nature of Suit:
Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision
Judge:
Firms
- Akin Gump
- Buttaci Leardi
- Carella Byrne
- Flitter Milz
- Green Savits
- King & Spalding
- Motley Rice
- Weissman & Mintz
Companies
- AARP Inc.
- American College of Physicians
- American Public Health Association
- American Society of Hematology
- Center for American Progress
- National Association for the Advancement of Colored People
- Novo Nordisk A S
- Public Citizen Inc.
- UnidosUS
Government Agencies
Sectors & Industries:
-
April 29, 2024
Judge Rejects 2 Challenges To Medicare Drug Price Talks
A New Jersey federal judge on Monday shot down a pair of challenges to the Medicare drug price negotiations, extending a string of court victories for the Biden administration as it defends the talks as entirely voluntary.
-
March 07, 2024
Judge Doubts Medicare Drug Pricing Amounts To 'Taking'
A New Jersey federal judge on Thursday bristled at the position by pharmaceutical companies that Medicare's drug price negotiation program is an unconstitutional "taking" that undercuts their bottom line, suggesting that the drug powerhouses needed more numbers to back their argument.
-
January 29, 2024
HHS Urges Court To Reject Novo Nordisk Drug Plan Challenge
The U.S. Department of Health and Human Services is asking a New Jersey federal judge to reject the challenge diabetes care drugmaker Novo Nordisk Inc. has been mounting against an effort to establish a drug price negotiation program aiming to lower costs for Medicare's prescription drug plan.
-
December 11, 2023
Novo Nordisk Says Fed Drug Pricing Unseen Even In Wartime
Novo Nordisk Inc. urged a New Jersey federal judge to grant it a win in its challenge to the Medicare drug price negotiation program, taking on both the Inflation Reduction Act's constitutionality as well as agency regulations implementing the law.
-
October 06, 2023
Mapping Big Pharma's Blitz On Medicare Drug Price Talks
Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.
-
October 02, 2023
Novo Nordisk Joins Fight With HHS Over Drug Price Talks
Novo Nordisk Inc. joined other Big Pharma companies on Friday suing over the Inflation Reduction Act's Medicare drug price negotiation provision, calling the program "extreme and unprecedented" in a lawsuit filed in New Jersey federal court.